Back to all bills
S 735119th CongressIntroduced
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Introduced: Oct 29, 2025
Healthcare
Standard Summary
Comprehensive overview in 1-2 paragraphs
This legislation reauthorizes and expands the federal sickle cell disease demonstration program under the Public Health Service Act, significantly increasing funding while broadening its scope to include treatment of complications and research into other heritable blood disorders through grants and cooperative agreements.
Key Points
- 1Amends the Public Health Service Act to expand program focus from basic prevention and treatment to comprehensive management of sickle cell disease complications and other heritable blood disorders.
- 2Increases annual funding from $4.455 million to $8.205 million for fiscal years 2025 through 2029 to support expanded research and treatment initiatives.
- 3Authorizes grants and cooperative agreements instead of contracts alone to increase flexibility for institutions conducting sickle cell disease prevention and treatment programs.
Impact Areas
Patients with sickle cell disease and heritable blood disordersPublic health agencies and research institutions conducting demonstrationsHealthcare providers specializing in hematology and genetic blood disorders
Generated by LegislativeCategorizerPro-2025 on Nov 2, 2025